Publication date: Jul 15, 2025
A rapid, sensitive, and selective reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the simultaneous determination of five COVID-19 antiviral drugs: favipiravir, molnupiravir, nirmatrelvir, remdesivir, and ritonavir. The chromatographic separation was achieved on a Hypersil BDS C18 column (4. 5 cD7 150 mm, 5 μm particle size) using an isocratic mobile phase consisting of water and methanol (30:70 v/v, pH 3. 0 adjusted with 0. 1% ortho-phosphoric acid) at a flow rate of 1 mL/min with UV detection at 230 nm. The optimized method demonstrated good chromatographic resolution with retention times of 1. 23, 1. 79, 2. 47, 2. 86, and 4. 34 min for favipiravir, molnupiravir, nirmatrelvir, remdesivir, and ritonavir, respectively. The method was validated according to ICH guidelines, showing linearity in the concentration range of 10-50 ug/mL with correlation coefficients (r^2) ≥ 0. 9997 for all analytes. The limits of detection were 0. 415-0. 946 ug/mL, while the limits of quantification were 1. 260-2. 868 ug/mL. The method demonstrated high trueness (99. 59-100. 08%) and precision (RSD
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Favipiravir |
| drug | DRUGBANK | Ritonavir |
| drug | DRUGBANK | Water |
| drug | DRUGBANK | Phosphoric acid |
| drug | DRUGBANK | Adenosine phosphate |
| drug | DRUGBANK | L-Alanine |